Clinical Trials

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

320 enrolled

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT06525246 2026-03-13

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

78 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06507306 2026-02-06

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

100 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

42 enrolled

CNS

Meningeal Carcinomatosis

NCT07315113 2026-01-02

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02157883 2025-11-19

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

39 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05954871 2025-11-13

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

10 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

80 enrolled

EGFR Positive Non-small Cell Lung Cancer

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

237 enrolled

Tumor-Agnostic

Neoplasms

NCT04721015 2025-07-03

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

81 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

246 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04862780 2025-02-10

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

177 enrolled

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05228015 2024-11-18

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Other solid neoplasmThoracic

67 enrolled

Mesothelioma, Malignant, Hemangioendothelioma, Epithelioid

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02163733 2024-01-22

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

38 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02923947 2023-11-27

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

16 enrolled

Renal Insufficiency

NCT04959981 2023-07-25

HERKULES-2

24 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Noonan Syndrome, Thoracic Neoplasms

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

20 enrolled

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03418532 2023-03-23

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

8 enrolled

EGFR-mutated NSCLC (Disorder)

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Withdrawn

NSCLC

NCT03463525 2023-01-27

ODIN-BM

4 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

24 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03255083 2022-01-19

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

13 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02228369 2021-01-05

BLOOM

108 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Phase 1 Unknown

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02529995 2020-02-11

AURAChinaPK

31 enrolled 22 charts

Tumor-Agnostic

Carcinoma

NCT02491944 2016-10-13

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291